New LEVEL UP Period 2 Data Shows Patients Who Switched From Dupilumab to Upadacitinib Achieved Higher Treatment Targets in AD

Christopher Bunick, MD, PhD, presented the latest period 2 data at Fall Clinical 2024.

Dermatology Times